Post-earnings recap
Reported
Thu, Aug 13, 2026
EPS actual
$1.04
EPS est.
$0.78
EPS surprise
+32.65%
1-day move
-3.61%
Ascendis Pharma's strong EPS performance indicates better-than-expected profitability, driven by significant product revenue growth. However, the stock fell by 3.61% following the earnings report, which may reflect investor concerns about future guidance or overall market conditions. The company is on track for substantial revenue growth, particularly with YORVIPATH achieving blockbuster status.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.04 | N/A | +32.65% |
| Product Revenue | EUR 315M | N/A | N/A |
| YORVIPATH Revenue | EUR 252M | N/A | N/A |
| YUVIWEL Revenue | EUR 8M | N/A | N/A |
Management expressed confidence in the company's growth trajectory, highlighting strong demand for YORVIPATH and the success of SKYTROFA. They reiterated their financial targets for the coming years.
Management reiterated guidance for >EUR 500M operating cash flow in 2026.
They aim for EUR 5B revenue by 2030.
SKYTROFA continues to lead as the number one long-acting growth hormone in the U.S.
Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. With a market cap of $16 billion, it operates in the health care sector, which is increasingly important as the demand for specialized medical treatments grows.
Last quarter
In Q1 2026, Ascendis Pharma reported an impressive EPS of $11.46, significantly exceeding expectations. However, revenue details were not disclosed, leaving some uncertainty about overall performance.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
50%
Avg EPS surprise
+537.34%
Avg 1-day reaction
+0.65%
Investors are cautiously optimistic ahead of the earnings report, especially after the strong surprise in Q1. However, the lack of analyst estimates adds uncertainty to expectations.
Bull case
If Ascendis continues its trend of beating EPS estimates and provides positive updates on its pipeline, the stock could see significant upward movement.
Bear case
Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could lead to a sharp decline in stock price.
The print will turn on these.
Q1
What is the current status of the drug pipeline and expected timelines for upcoming trials?
Updates on the pipeline will be critical for investors to gauge future revenue potential and the company's growth trajectory.
Q2
How is Ascendis managing its operational costs in light of recent EPS performance?
Understanding cost management will help investors assess the sustainability of the recent EPS surprise and overall profitability.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.8%
Why consensus could be wrong
The Street may be underestimating the impact of Ascendis' recent pipeline advancements, which could lead to stronger-than-expected revenue growth.
Supporting evidence
The significant EPS surprise in Q1 indicates potential for continued strong performance.
Options pricing suggests traders expect a larger move than historical averages, hinting at bullish sentiment.
Recent advancements in the pipeline have not been fully factored into market expectations.
Key risk
If the company provides strong updates on its pipeline, it could challenge current market skepticism.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to sustain its recent EPS performance while advancing its drug pipeline.
Bull confirmed if
A positive update on the drug pipeline with at least one new trial initiation would confirm the bull case.
Bear confirmed if
Any indication of delays or setbacks in the pipeline could confirm the bear case.
What the market is pricing for the move.
Implied Move
±9.25%
Historical Avg
±2.9%
The options market is pricing in a substantial move, suggesting that traders expect significant volatility around the earnings announcement.
Options are pricing ±9.3% while ASND has averaged ±2.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
41.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Ascendis beats expectations and raises guidance, history suggests the stock could rise by an average of 4.71%.
In line / cautious
If results are in line but management provides cautious commentary, the stock may experience a muted reaction.
Miss
If the company misses expectations, history suggests a potential decline of around 1.60%.
The lines on the call that would change the story.